Review Article
Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer
Table 1
Anti-angiogenic drugs approved by the United States Food and Drug Administration (2004–2012).
| | Anti-VEGF drug | Approved indication |
| | Bevacizumab | Metastatic colorectal cancer (with chemotherapy) | | Metastatic nonsquamous non-small cell lung cancer (with chemotherapy) | | Metastatic breast cancer (with chemotherapy) | | Recurrent glioblastoma (monotherapy) | | Metastatic renal cell carcinoma (with IFNα) | | Sunitinib | Metastatic renal cell carcinoma (monotherapy) | | Gastrointestinal stromal tumors (monotherapy) | | Pancreatic neuroendocrine tumors (monotherapy) | | Sorafenib | Metastatic renal cell carcinoma | | Unresectable hepatocellular carcinoma | | Pazopanib | Metastatic renal cell carcinoma | | Advanced soft tissue sarcoma | | Vandetanib | Advanced medullary thyroid cancer | | Axitinib | Advanced renal cell carcinoma | | Regoranfenib | Metastatic colorectal cancer | | Aflibercept | Metastatic colorectal cancer (with chemotherapy) | | Wet age-related macula degeneration | | Pegaptanib | Wet age-related macula degeneration | | Ranibizumab | Wet age-related macula degeneration |
|
|
